AKRX Share Price

Open 32.49 Change Price %
High 32.69 1 Day 0.13 0.40
Low 32.36 1 Week 0.00 0.00
Close 32.57 1 Month -0.65 -1.96
Volume 3867479 1 Year 10.39 46.84
52 Week High 34.00
52 Week Low 17.61
AKRX Important Levels
Resistance 2 32.88
Resistance 1 32.75
Pivot 32.54
Support 1 32.39
Support 2 32.26
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Akorn, Inc. (NASDAQ: AKRX)

AKRX Technical Analysis 2
As on 31st Oct 2017 AKRX Share Price closed @ 32.57 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 28.71 & Sell for SHORT-TERM with Stoploss of 32.94 we also expect STOCK to react on Following IMPORTANT LEVELS.
AKRX Target for April
1st Target up-side 33.22
2nd Target up-side 33.68
3rd Target up-side 34.14
1st Target down-side 31.92
2nd Target down-side 31.46
3rd Target down-side 31
AKRX Other Details
Segment EQ
Market Capital 1177286784.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.akorn.com
AKRX Address
1925 West Field Court
Suite 300
Lake Forest, IL 60045
United States
Phone: 847-279-6100
AKRX Latest News
Interactive Technical Analysis Chart Akorn, Inc. ( AKRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Akorn, Inc.
AKRX Business Profile
Akorn, Inc., incorporated on January 20, 1971, is a manufacturer and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. The Company operates in three segments: ophthalmic, hospital drugs & injectables, and contract services. The Company operates pharmaceutical manufacturing plants in the United States at Decatur, Illinois and Somerset, New Jersey, and internationally at Paonta Sahib, Himachal Pradesh, India, as well as a central distribution warehouse in Gurnee, Illinois, R&D centers in Skokie and Vernon Hills, Illinois and corporate offices in Lake Forest, Illinois. The Company’s customers include physicians, optometrists, hospitals, wholesalers, group purchasing organizations, retail pharmacy chains and other pharmaceutical companies. On February 28, 2012, the Company, through its wholly owned subsidiary, Akorn India Private Limited, acquired selected assets of Kilitch Drugs (India) Limited, and it also acquired selected assets of NBZ Pharma Limited. In November 2013, the Company acquired from Merck, the United States rights to three branded ophthalmic products, such as AzaSite, COSOPT and COSOPT PF, including those product rights obtained through the acquisition of Inspire Pharmaceuticals, Inc., a subsidiary of Merck. The Company operates pharmaceutical manufacturing facilities in Decatur, Illinois and Somerset, New Jersey, and in Paonta Sahib, Himachal Pradesh, India. Its Somerset facility manufactures ophthalmic solutions and ointment products for the Company’s ophthalmic and contract services segments, and gels for its hospital drugs & injectables segment. The Company’s Decatur manufacturing facility manufactures dye products, liquid injectables, lyophilized injectables and ophthalmic solutions for its ophthalmic, hospital drugs & injectables and contract services segments. The manufacturing complex in Paonta Sahib, Himachal Pradesh, India manufactures liquid generic pharmaceutical injectables, injectable and oral cephalosporins, sterile injectable carbapenems, hormones and oncology products. The Paonta Sahib plant manufactures product for Indian contract customers and for export to Africa, Asia and other unregulated markets.